Loading...
XTAI
1783
Market cap112mUSD
Jul 09, Last price  
40.35TWD
1D
-0.86%
1Q
-5.28%
Jan 2017
96.64%
IPO
95.78%
Name

Maxigen Biotech Inc

Chart & Performance

D1W1MN
XTAI:1783 chart
P/E
13.64
P/S
4.46
EPS
2.96
Div Yield, %
2.06%
Shrs. gr., 5y
2.14%
Rev. gr., 5y
12.14%
Revenues
812m
+19.23%
180,604,000172,440,000178,876,000221,997,000232,947,000245,686,000261,469,000336,388,000427,561,000427,680,000452,199,000457,691,000511,976,000604,431,000622,115,000680,651,000811,564,000
Net income
265m
+39.52%
12,627,000-16,000,000-36,073,0002,764,0002,584,000-19,041,000-62,959,000-12,247,00015,787,00057,055,00060,111,00063,311,00087,667,000139,404,000165,828,000190,167,000265,312,000
CFO
290m
-2.68%
19,271,000-16,764,000-76,640,00017,526,000-22,336,000-14,451,000-109,850,00034,718,00041,176,000170,581,00094,418,00074,394,000117,593,000268,338,000171,200,000298,223,000290,220,000
Dividend
Sep 05, 20250.82996 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Maxigen Biotech Inc. (MBI) is a company dedicated to the research, development, production, and global commercialization of advanced biomedical and skincare solutions. Its extensive biomedical portfolio includes various orthopedic products such as Formagraft, a bone graft substitute, and Formasetin, a bone void filler. For intra-articular applications in orthopedics, MBI markets injections under the names ArtiAid, ArtiAid Plus, and ArtiBest. The company's offerings also span both orthopedic and dental fields, featuring Foramic, a bone substitute granule; MaxiBone, a calcium phosphate ceramic; and GingivAid, a collagen dental graft. Specifically for dental use, MBI provides FormaAid, a collagen membrane, and the E-TECH DENTISTAR II sterilizer and disinfectant. Furthermore, HealiAid, a collagen wound dressing product, serves dental and general wound care purposes. MBI also manufactures ophthalmic viscoelastic devices, known as ViscAid, PreviscAid, and BiVisc, and produces Formaderm, a dermal filler injection utilized in plastic surgery. Beyond its medical devices, Maxigen Biotech Inc. offers a comprehensive line of skincare products. This array includes masks for the face, neck, body, and limbs, alongside make-up removers, cleansers, exfoliants, toners, essences, men's grooming items, sunscreens, and specialized body, hand, and foot care formulations. Maxigen Biotech Inc. was established in 1998 and operates from its main office in Taoyuan City, Taiwan.
IPO date
May 18, 2011
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT